Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Strategy

Passing the baton

Challenges and opportunities for Novartis’ CEO designate Narasimhan

September 16, 2017 4:12 AM UTC

When he takes the helm as CEO of Novartis AG in January, Vasant Narasimhan will inherit a business that is still struggling to plug the revenue hole from cancer drug Gleevec imatinib going off patent in February 2016.

The pharma’s big bet on heart failure drug Entresto sacubitril/valsartan, launched in 2015, is dogged by slow uptake, and the Alcon Inc. eye care business fully acquired in 2011 is declining...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Novartis AG